Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENGNNASDAQ:ITOSNASDAQ:SOPHNASDAQ:TCRR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENGNenGene$4.00-0.7%$5.37$3.50▼$16.62$203.91M-0.38131,298 shs137,284 shsITOSiTeos Therapeutics$5.18-3.9%$6.78$4.80▼$18.75$197.85M1.43462,462 shs387,537 shsSOPHSOPHiA GENETICS$2.79-5.1%$3.42$2.60▼$6.28$186.06M1.0266,280 shs8,570 shsTCRRTCR2 Therapeutics$1.48$1.65$0.82▼$3.88$58.11M1.95494,777 shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENGNenGene-2.18%-9.23%-23.09%-50.25%-75.11%ITOSiTeos Therapeutics+6.94%-6.59%-22.45%-30.99%-57.39%SOPHSOPHiA GENETICS+10.53%-10.64%-8.41%+1.38%-40.85%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENGNenGene2.9718 of 5 stars3.55.00.00.01.92.50.6ITOSiTeos Therapeutics2.7944 of 5 stars3.53.00.00.03.22.50.6SOPHSOPHiA GENETICS2.5336 of 5 stars3.45.00.00.03.10.00.6TCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENGNenGene 3.00Buy$25.22530.56% UpsideITOSiTeos Therapeutics 3.00Buy$25.75397.10% UpsideSOPHSOPHiA GENETICS 2.75Moderate Buy$6.80143.73% UpsideTCRRTCR2 Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TCRR, ENGN, ITOS, and SOPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/11/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.003/11/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/6/2025SOPHSOPHiA GENETICSBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.003/6/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$19.00 ➝ $17.003/6/2025ITOSiTeos TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$22.00 ➝ $15.003/6/2025ITOSiTeos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/5/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.002/18/2025ENGNenGenePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.002/14/2025ENGNenGeneUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$34.00 ➝ $7.001/16/2025ITOSiTeos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.001/10/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.00(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENGNenGeneN/AN/AN/AN/A$6.17 per shareN/AITOSiTeos Therapeutics$35M5.65N/AN/A$16.08 per share0.32SOPHSOPHiA GENETICS$65.17M2.85N/AN/AN/A∞TCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENGNenGene-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%N/AITOSiTeos Therapeutics-$112.64M-$3.31N/AN/AN/AN/A-20.11%-17.50%5/9/2025 (Estimated)SOPHSOPHiA GENETICS-$78.98M-$0.95N/AN/AN/A-110.71%-55.06%-38.33%5/6/2025 (Estimated)TCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/ALatest TCRR, ENGN, ITOS, and SOPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21N/AN/AN/A$16.76 millionN/A3/5/2025Q4 2024ITOSiTeos Therapeutics-$1.14-$1.01+$0.13-$1.01N/AN/A3/4/2025Q4 2024SOPHSOPHiA GENETICS-$0.23-$0.23N/A-$0.23$17.71 million$17.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENGNenGene$1.5839.52%N/AN/A N/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENGNenGene0.0816.8716.87ITOSiTeos TherapeuticsN/A14.8014.80SOPHSOPHiA GENETICS0.123.803.59TCRRTCR2 TherapeuticsN/A2.962.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENGNenGene64.16%ITOSiTeos Therapeutics97.16%SOPHSOPHiA GENETICS31.59%TCRRTCR2 Therapeutics64.76%Insider OwnershipCompanyInsider OwnershipENGNenGene13.70%ITOSiTeos Therapeutics12.50%SOPHSOPHiA GENETICS4.88%TCRRTCR2 Therapeutics25.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENGNenGene3150.98 million38.16 millionN/AITOSiTeos Therapeutics9038.19 million31.97 millionOptionableSOPHSOPHiA GENETICS52066.69 million62.19 millionNot OptionableTCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableTCRR, ENGN, ITOS, and SOPH HeadlinesRecent News About These CompaniesTCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatmentApril 17, 2024 | pharmaceutical-technology.comPoseida Therapeutics Inc Ordinary Shares PSTXFebruary 25, 2024 | morningstar.comDICE Therapeutics Inc.June 20, 2023 | wsj.comAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy CompanyJune 1, 2023 | finance.yahoo.comTCR2 Therapeutics Insider Trades Send a SignalMay 16, 2023 | benzinga.comRecap: TCR2 Therapeutics Q1 EarningsMay 12, 2023 | msn.com10-Q: TCR2 THERAPEUTICS INC.May 11, 2023 | marketwatch.comTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | finance.yahoo.comCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite RiskyApril 15, 2023 | finance.yahoo.comMizuho Downgrades Tcr2 Therapeutics (TCRR)March 25, 2023 | msn.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho SecuritiesMarch 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)March 23, 2023 | markets.businessinsider.comTCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 23, 2023 | finanznachrichten.deTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 23, 2023 | finance.yahoo.comWhat To Know About Jefferies's Downgrade of TCR2 TherapeuticsMarch 9, 2023 | msn.com4 Analysts Have This to Say About TCR2 TherapeuticsMarch 9, 2023 | markets.businessinsider.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. WainwrightMarch 8, 2023 | markets.businessinsider.comShareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with AdaptimmuneMarch 6, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. BuyoutMarch 6, 2023 | benzinga.comWhy Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?March 6, 2023 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCRR, ENGN, ITOS, and SOPH Company DescriptionsenGene NASDAQ:ENGN$4.00 -0.03 (-0.74%) Closing price 04:00 PM EasternExtended Trading$3.99 -0.01 (-0.25%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.iTeos Therapeutics NASDAQ:ITOS$5.18 -0.21 (-3.90%) Closing price 04:00 PM EasternExtended Trading$5.18 0.00 (0.00%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.SOPHiA GENETICS NASDAQ:SOPH$2.79 -0.15 (-5.10%) Closing price 04:00 PM EasternExtended Trading$2.84 +0.04 (+1.61%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.TCR2 Therapeutics NASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Delta, Walmart Cut Profit Targets: Could Start Domino Effect Joby Aviation: Operational Momentum vs. Market Sentiment Carvana: Can Turnaround Strength Outdrive Market Headwinds? Is Alphabet a Generational Buying Opportunity at These Levels? Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
